drugset / Trial / NCT02211261
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupDouble-blindBasic science
Summary
A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
Timeline
- Start
- 2014-09-15
- Primary completion
- 2017-01-27
- Completion
- 2017-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PF-06293620 | Unknown | 0.3 mg/kg | Subcutaneous |
| Subject | PF-06293620 | Unknown | 1 mg/kg | Subcutaneous |
| Subject | PF-06293620 | Unknown | 3 mg/kg | Subcutaneous |
| Subject | PF-06293620 | Unknown | 6 mg/kg | Subcutaneous |
| Subject | PF-06293620 | Unknown | 75 mg | Subcutaneous |
| Subject | PF-06293620 | Unknown | 150 mg | Subcutaneous |
| Subject | PF-06293620 | Unknown | 250 mg | Subcutaneous |